纳他霉素与伏立康唑对镰刀菌属、念珠菌属、曲霉属和弯孢菌属临床分离株的体外协同作用
本研究为体外实验,采用棋盘微量稀释法和分级抑菌浓度(FIC)指数模型,检测纳他霉素与伏立康唑单用及联用对镰刀菌属、曲霉属、念珠菌属和弯孢菌属临床分离株的最低抑菌浓度(MIC)。两药单用MIC均为0.125–8 µg/mL;联用后各菌属均以协同或相加为主,未见拮抗,作者认为该组合可能有助于治疗真菌性角膜炎。
要点
- 纳他霉素与伏立康唑单用MIC均为0.125–8 µg/mL。
- 协同作用以念珠菌属最高(33.3%),曲霉属最低(22.2%)。
- 所有受试菌株均未观察到拮抗作用。
核心结论
- 纳他霉素与伏立康唑联用在所有受试菌种的体外实验中显示出比单药更有效的抗真菌活性,提示该组合可能有助于治疗真菌性角膜炎,两药之间无拮抗作用。
研究设计与样本
- 体外实验研究,临床分离的镰刀菌属、曲霉属、念珠菌属和弯孢菌属菌株保存于沙氏葡萄糖琼脂培养基。
- 按临床实验室标准研究所(CLSI)推荐的标准方案,采用棋盘微量稀释技术检测纳他霉素与伏立康唑单用及联用的MIC。
- 采用分级抑菌浓度(FIC)指数模型评估两药相互作用。
主要发现
- 所有临床分离株检测中,纳他霉素与伏立康唑的MIC范围均为0.125–8 µg/mL。
- 协同作用(FIC≤0.5)按降序为念珠菌属33.3%、弯孢菌属与镰刀菌属23.1%、曲霉属22.2%。
- 相加作用(>0.5–1)以曲霉属最高61.5%(8/13)、念珠菌属最低33.3%(2/6)。
- 无差异(FIC>1且≤4)见于曲霉属22.2%(2/9)、镰刀菌属15.4%(2/13)、念珠菌属33.3%(2/6)、弯孢菌属23.1%(3/13)。
- 未观察到拮抗(FIC>4)病例。
临床怎么用
- 作者认为纳他霉素与伏立康唑联用可能有助于治疗真菌性角膜炎。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To determine the minimum inhibitory concentrations (MICs) of voriconazole and natamycin, alone and in combination, against the clinical isolates of Fungus and to evaluate the synergy between the drugs in an experimental in vitro study. METHODS: In an experimental in vitro study, clinical isolates of Fusarium, Aspergillus, Candida and Curvularia spp were maintained on Sabouraud Dextrose Agar and used for the study. The MICs of natamycin and voriconazole, used alone and in combination, were evaluated by checkerboard microdilution technique based on the standard protocol proposed by the Clinical Laboratory Standards Institute. The interactions were assessed using the fractional inhibitory concentration (FIC) Index model. RESULTS: Tested with all the clinical isolates, the MICs ranged between 0.125 and 8 µg/mL both for natamycin and voriconazole. In descending order, maximum synergism (FIC ≤0.5) was observed in Candida spp (33.3%) followed by Curvularia spp and Fusarium spp (23.1%). Synergism was least for Aspergillus spp (22.2%). However, at 61.5% (8/13), maximum additive effect (>0.5-1) was observed in Aspergillus spp and minimum (33.3%, 2/6) in Candida spp. Indifference (FIC value >1 and≤4) was observed in 22.2% (2/9) of Aspergillus spp, 15.4% (2/13) of Fusarium spp, 33.3% (2/6) of Candida spp and 23.1% (3/13) of Curvularia spp. No cases of antagonism (FIC >4) were observed. CONCLUSIONS: Natamycin and voriconazole in combination demonstrated more effective antifungal activity than single-use in vitro treatment in all species tested, which implies that these combinations may be helpful in treating fungal keratitis. There was no antagonism between these two drugs.
引用
- Sradhanjali S, Yein B, Sharma S, et al. In vitro synergy of natamycin and voriconazole against clinical isolates of Fusarium, Candida, Aspergillus and Curvularia spp. Br J Ophthalmol. 2017. PMID: 28982951. doi:10.1136/bjophthalmol-2017-310683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。